Anlene CholestoPro offers dual action formula, supporting cholesterol levels & mobility
KUALA LUMPUR: Nearly one in three Malaysians suffers from high cholesterol, but more than half remain unaware due to the absence of early symptoms, making it one of the country's leading 'silent killers' linked to heart attacks and strokes.
Despite the growing health concern, awareness of routine health screenings and lifestyle changes remains low, particularly among those aged 35 and above.
In response, Anlene has launched Anlene CholestoPro, a new milk formulation with a dual-action blend of nutrients designed to support both optimal cholesterol levels and mobility, which includes bone, joint and muscle health.
The product contains 1.2 grams of plant sterols in two daily servings, clinically proven to help reduce cholesterol.
It also provides 100 per cent of the recommended daily intake of calcium and vitamin D, along with protein, collagen and vitamin C to support overall movement and wellness.
Anlene said the new product encourages a proactive approach to health, particularly for adults at higher risk of cardiovascular issues.
NATIONWIDE ROADSHOW
In conjunction with the launch, Anlene is conducting a nationwide health roadshow at selected locations until July. Members of the public can undergo free cholesterol checks, bone scans and muscle strength assessments to better understand their health status.
A combination of a balanced diet and an active lifestyle remains the most effective strategy to manage cholesterol levels and maintain long-term health, especially among middle-aged individuals.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
13 hours ago
- The Sun
Duopharma Biotech secures halal certification for biosimilar anaemia treatment
KUALA LUMPUR: Duopharma Biotech Bhd has achieved another milestone in the halal pharmaceutical sector with the halal certification of a biosimilar product used to treat anaemia in patients with chronic renal failure. The certification, awarded by the Department of Islamic Development Malaysia (JAKIM), strengthens Duopharma's position at the forefront of Malaysia's halal pharmaceutical sector. Group Managing Director Leonard Ariff Abdul Shatar said the product is used in adult and paediatric patients undergoing haemodialysis or the predialysis stage. It is currently supplied to both public and private healthcare facilities nationwide. 'This certification marks a key advancement in the company's biologics journey and will further motivate our efforts to provide consumers and patients with access to medicines and therapies that are assured safe and effective, high in quality, hygienic and halal from the start,' Leonard Ariff said referring to the product which is manufactured at Duopharma's plant in Klang. He added that the certification is timely, given the rising number of dialysis patients in Malaysia. The Ministry of Health projects that over 106,000 Malaysians may require dialysis by 2040, with more than 10,000 new cases annually if current trends persist. Duopharma has been a pioneer in the biologics, having launched Malaysia's first Phase 3 clinical trial for an Epoetin Alfa biosimilar in 2014 with South Korea's Pangen Biotech Inc. In 2018, it became the first Malaysian company to install a biologic pre-filled syringe production line. The company also promotes the halal pharmaceutical agenda globally through the annual Halal Pharmaceuticals Symposium, which it has hosted since 2016, bringing together global experts, regulators and industry leaders to advance halal integration in the healthcare system.
The Sun
13 hours ago
- The Sun
Duopharma Biotech secures halal cert for anaemia treatment
KUALA LUMPUR: Duopharma Biotech Bhd has achieved another milestone in the halal pharmaceutical sector with the halal certification of a biosimilar product used to treat anaemia in patients with chronic renal failure. The certification, awarded by the Department of Islamic Development Malaysia (JAKIM), strengthens Duopharma's position at the forefront of Malaysia's halal pharmaceutical sector. Group Managing Director Leonard Ariff Abdul Shatar said the product is used in adult and paediatric patients undergoing haemodialysis or the predialysis stage. It is currently supplied to both public and private healthcare facilities nationwide. 'This certification marks a key advancement in the company's biologics journey and will further motivate our efforts to provide consumers and patients with access to medicines and therapies that are assured safe and effective, high in quality, hygienic and halal from the start,' Leonard Ariff said referring to the product which is manufactured at Duopharma's plant in Klang. He added that the certification is timely, given the rising number of dialysis patients in Malaysia. The Ministry of Health projects that over 106,000 Malaysians may require dialysis by 2040, with more than 10,000 new cases annually if current trends persist. Duopharma has been a pioneer in the biologics, having launched Malaysia's first Phase 3 clinical trial for an Epoetin Alfa biosimilar in 2014 with South Korea's Pangen Biotech Inc. In 2018, it became the first Malaysian company to install a biologic pre-filled syringe production line. The company also promotes the halal pharmaceutical agenda globally through the annual Halal Pharmaceuticals Symposium, which it has hosted since 2016, bringing together global experts, regulators and industry leaders to advance halal integration in the healthcare system.
Malaysiakini
16 hours ago
- Malaysiakini
Govt must ban sale of vape to safeguard public health
MP SPEAKS | As a concerned MP, I strongly assert that the use of electronic cigarettes or vapes poses a serious threat to the health of Malaysians, especially the younger generation. Recent data shows an alarming increase in vape usage among teenagers. In 2022, 14.9 percent of youths aged 13–17 in the country were reported to be vaping, up from just 9.8 percent in 2017. This sharp rise not only reflects the spread of nicotine addiction among youths but also carries serious health implications. Therefore, I urge the government to take firm action by fully banning the sale and distribution of vapes to safeguard the well-being of future generations. Medical research has clearly proven that vaping is harmful to the body. The nicotine in vape liquids is highly addictive, particularly for teenagers, and can disrupt brain development and cognitive functions. Researchers have found that nicotine can alter brain chemistry, affect memory and concentration, and increase the risk of anxiety, depression, and addiction to other substances. Malaysia has already witnessed serious incidents involving vaping, including seizures, breathing difficulties, and even deaths linked to excessive vape use or contaminated vape liquids. The Health Ministry has confirmed that e-cigarettes or vapes are not a safe alternative to quitting smoking and have adverse effects on health. Latest statistics related to vape-induced illnesses reinforce this concern. As of June 2023, the ministry recorded 17 cases of vaping-associated lung injury (evali) nationwide. Death risk Tragically, Malaysia also reported its first vape-related death: a 16-year-old girl who had been vaping for three years died on June 5, 2023 from acute heart failure in a case classified as evali. In another incident, a two-year-old child suffered nicotine poisoning after ingesting vape liquid, leading to serious and prolonged neurological complications. The rising number of such cases demonstrates the critical situation posed by vape usage in our society. Scientific findings further support this call for a ban. Medical experts have confirmed that the chemicals in heated vape liquids can damage lung tissue, triggering inflammation of the lung lining and raising the risk of lung injury. International studies have also found that e-cigarette use increases the long-term risk of respiratory diseases. For example, a recent cohort study in the United States reported that the risk of chronic obstructive pulmonary disease (COPD) is more than twice as high among vape users compared to those who have never smoked or vaped. Even without nicotine, flavouring agents in vape products have been shown in lab and animal studies to pose risks to the heart and lungs. The high nicotine content also causes a sharp increase in heart rate and blood pressure, indicating negative effects on the cardiovascular system. Clearly, vaping not only leads to addiction but also raises the risk of chronic illnesses and long-term health complications. High cost This vaping phenomenon also significantly burdens the public healthcare system. The cost of treating vape-related illnesses is extremely high and will strain taxpayers. The Health Ministry estimates that the treatment cost for a single evali patient can reach RM150,000. Without effective control measures, vape-related healthcare spending is projected to rise to RM369 million per year by 2030. This figure nearly matches the projected vape tax revenue of around RM500 million annually, demonstrating that the economic benefits of the vape industry are far outweighed by the health costs borne by the government. The public healthcare sector risks losing hundreds of millions of ringgit to treat vape-related complications, funds that could otherwise be used for more urgent health needs. Concerns over the vape threat are also echoed by state governments, with Johor, Kedah, and Terengganu taking bold steps by not renewing licenses for vape retailers, effectively banning vape sales in those states. These decisive actions reflect the commitment of those states to protect their citizens, especially the youth, from the dangers of vaping. However, such efforts need to be expanded nationally to ensure comprehensive public health protection, rather than relying solely on state-by-state measures. Tighten laws At the federal level, existing regulatory measures are still weak. Last year, the government removed nicotine-containing vape liquids from the Poisons Act 1952, allowing the unrestricted sale of nicotine vape products. This decision led to a rapid expansion of the vape market, making it increasingly difficult to control particularly among youth. Although Parliament recently passed the Control of Smoking Products for Public Health Bill 2023, the crucial Generational End Game (GEG) clause, which aimed to ban the sale of nicotine products to anyone born after 2007 was unfortunately dropped. This was a major missed opportunity to protect the younger generation from addiction. Without such critical provisions and comprehensive vape regulation, efforts to curb nicotine addiction among youth will become even more challenging. A complete nationwide ban on the sale and distribution of vapes must be implemented immediately. This bold move is essential to stem the growing vape epidemic, protect the health of our youth, and relieve the burden on our public healthcare system. The government is urged not to prioritise short-term tax revenue over the long-term well-being of the people. Instead, it should prioritise the future of our younger generation by enforcing a comprehensive ban on vape, ensuring a healthier, vape-free Malaysia. R YUNESWARAN is the MP for Segamat. The views expressed here are those of the author/contributor and do not necessarily represent the views of Malaysiakini.
